
June 30 (Reuters) - Gain Therapeutics Inc GANX.O:
GAIN THERAPEUTICS ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 1B CLINICAL STUDY EVALUATING GT-02287 IN PEOPLE WITH PARKINSON’S DISEASE WITH OR WITHOUT A GBA1 MUTATION
GAIN THERAPEUTICS INC - BIOMARKER ANALYSIS EXPECTED IN 4Q 2025, EARLIER THAN PLANNED
GAIN THERAPEUTICS INC - EXTENDS SCREENING FOR PHASE 1B TRIAL THROUGH JULY 31, 2025